Letrozole Eg (Letrozole)

Letrozole works by selectively inhibiting the aromatase enzyme, which converts adrenal and peripheral androgens into estrogens. This inhibition markedly reduces circulating estrogen levels, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing cancer progression.

The prescribing clinician determines the appropriate dose for each patient. In adult practice, a common regimen is 2.5 mg taken orally once daily, but the exact dosage and schedule are individualized based on clinical judgment and patient factors.

Letrozole is contraindicated in pregnancy and is not recommended for breastfeeding women. Its safety profile has not been established for these populations, and exposure could pose risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, anastrozole, and exemestane are all aromatase inhibitors used in postmenopausal breast cancer. Letrozole is often considered the most potent inhibitor of estrogen synthesis, offering slightly higher efficacy in some trials, while anastrozole has a similar safety profile and exemestane is a steroidal inhibitor with distinct metabolic characteristics.

Letrozole Eg should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains sealed until use.

Letrozole Eg is taken orally as a tablet, usually once daily. It can be swallowed with water and may be taken with or without food, according to the prescriber's instructions.

Serious risks include severe liver injury, significant bone loss leading to fractures, thromboembolic events such as pulmonary embolism, and rare but potentially life‑threatening allergic reactions. Patients should be monitored regularly for signs of these complications.

Letrozole should not be used in premenopausal women, patients with known hypersensitivity to letrozole or other aromatase inhibitors, individuals with severe hepatic impairment, and anyone who is pregnant or breastfeeding.